Clinical trials: Girls
Renal Cell Carcinoma
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
This multicenter, randomized, open-label study will evaluate the efficacy, safety and tolerability of atezolizumab as monotherapy or in combination with bevacizumab versus sunitinib in participants with histologically confirmed…
- Trial name
- IMmotion150 (NCT01984242)
- Testing
- Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, Sunitinib
- Where
- 45 sites in United States, Czechia and 7 more
- Volunteers
- 305 people
- Sponsor
- Hoffmann-La Roche
Urinary Incontinence
Mixed Incontinence: Medical Or Surgical Approach?
The purpose of this study is to compare treatment outcomes for patients with mixed urinary incontinence (MUI) for whom therapy is initiated with surgery to those for whom therapy is initiated with non-surgical treatment.
- Trial name
- MIMOSA (NCT00803270)
- Testing
- Non-Surgical Intervention, Surgical
- Where
- 10 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Carelon Research
Women Contraception
Adiana Post-Approval Clinical Study (APACS)
The Adiana Post-Approval Clinical Study (APACS) has been designed to compile information on the efficacy and safety of the Adiana Permanent Contraception System in the post market setting.
- Trial name
- APACS (NCT01177670)
- Where
- 9 sites in United States
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Hologic, Inc.
Polycystic Ovary Syndrome
A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol
The purpose of this study is to determine the efficacy of Lipitor (Atorvastatin) for the treatment of PCOS with elevated LDL cholesterol.
- Trial name
- NCT00529542
- Testing
- Lipitor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Infertility
A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment
This trial investigates the effects of several doses of FE 999049 in women undergoing IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) treatment.
- Trial name
- NCT01426386
- Testing
- FE 999049, Gonal - F
- Where
- 8 sites in Belgium, Czechia and 2 more
- Volunteers
- 265 people
- Sponsor
- Ferring Pharmaceuticals
Erythema, Edema
A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects
To evaluate the safety of a personal lubricant when used as indicated as a personal lubricant in the vagina and vulvar/perineal areas at least four times weekly for two weeks in a population of healthy females
- Trial name
- NCT02320227
- Testing
- Miami w/o frag Personal lubricant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well lapatinib works in treating patients with persistent or recurrent ovarian epithelial or…
- Trial name
- NCT00113373
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Ureteral Obstruction
Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
The purpose of this study is to evaluate the safety and efficacy of the Memokath 051 ureteral stent as a long-term temporary and minimally invasive means of providing ureteral drainage in the setting of malignant extrinsic…
- Trial name
- NCT00166361
- Testing
- Memokath 051 Ureteral Stent, JJ Stent
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Chronic Kidney Disease
Home-Based Exercise to Treat Decreased Physical Function in Patients With Varying Levels of Kidney Function
The investigators will conduct a pilot study to determine whether home-based exercise is an effective intervention to improve decreased physical function in kidney transplant candidates.
- Trial name
- NCT04745169
- Testing
- 8 week home-based exercise program
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Polycystic Kidney Disease, Adult, ADPKD
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy of lixivaptan in participants who previously experienced liver chemistry test abnormalities while treated with…
- Trial name
- ALERT (NCT04152837)
- Testing
- Lixivaptan
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Palladio Biosciences
Urinary Bladder Diseases, Urinary Bladder Overactive
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence…
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- Trial name
- BESIDE (NCT01908829)
- Testing
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg
- Where
- 219 sites in United States, Armenia and 29 more
- Volunteers
- 2,174 people
- Sponsor
- Astellas Pharma Europe Ltd.
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies the side effects and how well sunitinib malate works in treating patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer
- Trial name
- NCT00388037
- Testing
- sunitinib malate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1 Infection
HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
Women sometimes develop cancer in an area called the cervix, which is the opening to the uterus, or womb. Women who have HIV are more likely to get this kind of cancer than women who do not have HIV.
- Trial name
- NCT01315353
- Testing
- Cervical Cryotherapy, Loop Electrosurgical Excision Procedure (LEEP)
- Where
- 13 sites in Botswana, Haiti and 5 more
- Volunteers
- 467 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Tobacco Use Disorder
Project 4, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Pregnant Women
Study 2 will evaluate the effects of extended exposure to cigarettes with varying levels of nicotine in pregnant smokers who have less than an Associate's degree. This study will be limited to two conditions: usual brand vs.
- Trial name
- NCT04033237
- Testing
- Very low nicotine content cigarettes
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Renal Insufficiency
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial.
- Trial name
- RESCUE (NCT00650845)
- Testing
- Dotarem®-enhanced MRI, non-enhanced MRI
- Where
- 15 sites in Belgium, France and 2 more
- Volunteers
- 135 people
- Sponsor
- Guerbet
Healthy
Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets
To establish bioequivalence (BE) under fed conditions between metformin in linagliptin/metformin fixed dose combination tablet and metformin reference product administered in free combination togther with linagliptin
- Trial name
- NCT01581931
- Testing
- Linagliptin/metformin, Metformin, Linagliptin
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Nocturnal Enuresis
Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis
This is multi-center, randomized, placebo-controlled, parallel-group, double-blind, dose-escalating clinical trial designed to assess the efficacy and safety of desmopressin orally lyophilisate for the treatment of nocturnal…
- Trial name
- PNE (NCT01078753)
- Testing
- Desmopressin
- Where
- 15 sites in Japan
- Volunteers
- 89 people
- Sponsor
- Ferring Pharmaceuticals
Healthy
This Study in Healthy Men and Women Tests How the Body Takes up BI 409306
The primary objective of this trial is to investigate the absolute bioavailability of BI 409306. The secondary objective is the evaluation and comparison of several pharmacokinetic parameters for the different treatments.
- Trial name
- NCT03505151
- Testing
- BI 409306 (C-13/N-15), BI 409306
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer, Primary PERITONEUM
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
The purpose of this study is to test whether it is safe to treat your cancer with 3 drugs instead of 2 drugs. After surgery, your cancer is typically treated with 2 drugs called cisplatin and paclitaxel (also known as Taxol).
- Conditions
- Ovarian Cancer, Primary PERITONEUM, Fallopian Tube Cancer
- Trial name
- NCT00588237
- Testing
- Paclitaxel,Cisplatin, Bevacizumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.